BTIG Research downgraded OraSure Technologies (NASDAQ:OSUR) from Buy to Neutral in a report released today.
- Updated: September 19, 2016
BTIG Research has downgraded OraSure Technologies(NASDAQ:OSUR) from Buy to Neutral in a statement released on 9/19/2016.
Having a price of $8.65, OraSure Technologies (NASDAQ:OSUR) traded 0.00% even on the day. The last close is up 21.64% relative to the 200-day moving average, compared with the S&P 500 Index which has fallen -0.01% over the date range. OraSure Technologies has recorded a 50-day moving average of $7.55 and 200-day moving average of $7.11. Volume of trade was was down over the average, with 0 shares of OSUR changing hands under the typical 1,001,370 shares.
See Graph Below:
OraSure Technologies has a 52 week low of $4.39 and a 52 week high of $9.05 with a price-earnings ratio of 41 and has a market cap of $0.0.
Also covering OraSure Technologies’s stock price target, a total of 5 brokerages have reported on OraSure Technologies. The 12-month target stock price is $8.60 with 0 rating the stock a strong buy, 0 rating the stock a buy, 0 firms rating the stock a hold, 0 rating the company to underperform, and lastly 0 brokeragesrating the stock as sell.
Brief Synopsis On OraSure Technologies (NASDAQ:OSUR)
OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Its diagnostic products include tests, such as OraQuick Rapid HIV Test, OraQuick In-Home HIV Test, OraQuick HIV Self-Test, OraQuick HCV Rapid Antibody Test, OraQuick Ebola Rapid Antigen Test, OraSure QuickFlu Rapid Flu A&B Test, OraSure Collection Device, Molecular Collection Systems, Cryosurgical Systems (Skin Lesion Removal Products), Immunoassay Tests and Reagents, and Western blot HIV-1 Confirmatory Test and Q.E.D. Saliva Alcohol Test. Its products are sold in the United States and internationally to clinical laboratories and hospitals.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.